Table 1.
Cognitively healthy participant demographic and baseline data.
Table 2.
MCI participant demographic and baseline data.
Figure 1.
Annual atrophy rates for MCI participants, with 95% confidence intervals, for AD-relevant cortical and subcortical ROIs, grouped with respect to baseline Aβ, ptau, and volumetric MRI status (top row).
In the bottom row, all participants are Aβ-positive. N is the number of participants. Numerical values are in File S1, Tables S1A–F.
Figure 2.
Annual atrophy rates for (A) Aβ+ HC participants, 4 of whom converted to MCI, and (B) Aβ+Ptau+ HCs participants (i.e., the HCs most likely to be preclinical-AD), 3 of whom converted to MCI, compared with the control group of stable Aβ– HCs.
N is the number of participants. Numerical values, including p-values, are in File S1, Tables S2A and S2B.
Figure 3.
Estimated sample sizes, per arm, to detect a 25% reduction in annual rate of change in MCI participants under several enrichment strategies, relative to the annual rate of change in amyloid-negative stable HCs, at the p<0.05 level with 80% power assuming a 24 month trial with scans every six months.
Sample sizes are estimated using a linear mixed effects model with fixed intercepts (no relative change at baseline) and random slopes applied to all data available up through 36 months. Error bars show the 95% confidence intervals. N is the number of participants. All numerical values are shown Table 3; p-values for comparisons are in Tables 4 and 5.
Table 3.
MCI sample size estimates for structural measures and a clinical measure – without enrichment, and with respect to five enrichment strategies.
Table 4.
P-values for significance of difference in sample size estimates (Table 3, Figure 3) from pairs of enrichment specifications (rows) for particular measures (columns).
Table 5.
P-values for significance of difference in sample size estimates (Table 3, Figure 3) from pairs of measures (rows) using particular enrichment specifications (columns).